Assessing surrogates as trial endpoints using mixed models

Statistics in Medicine

Volumn 24, Issue 2, 2005, Pages 163-182

  Korn, Edward L ^a   Albert, Paul S ^a   McShane, Lisa M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Fixed effects; Meta analysis; Random effects; Surrogate endpoints; Surrogate outcomes

Indexed keywords

ARTICLE; CLINICAL STUDY; HUMAN; MEDICAL RESEARCH; METHODOLOGY; PREDICTION; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; COMPUTER SIMULATION; FEMALE; HIV INFECTIONS; HUMANS; META-ANALYSIS; MODELS, STATISTICAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 12344270270     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1779     Document Type: Article

References (26)

1. Ellenberg SS, Hamilton JM. Surrogate endpoints in clinical trials: cancer. Statistics in Medicine 1989; 8:405-413.
2. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Statistics in Medicine 1989; 8:415-425.
3. Hillis A, Seigel D. Surrogate endpoints in clinical trials: ophthalmologic disorders. Statistics in Medicine 1989; 8 427-430.
4. Fleming TR. Evaluating therapeutic interventions: some issues and experiences (with discussion). Statistical Science 1992; 4 428-456.
5. Fleming TR. Surrogate markers in AIDS and cancer trials. Statistics in Medicine 1994; 13:1423-1435.
6. Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. Journal of the National Cancer Institute 1992; 84:407-414.
7. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16 1965-1982.
8. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998; 17:2815-2834.
9. Buyse M, Molensberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1:49-67.
10. Korn EL, Simon R. Explained residual variation, explained risk, and goodness of fit. American Statistician 1991; 45 201-206.
11. Carroll RJ, Ruppert D, Stefanski LA. Measurement Error in Nonlinear Models. Chapman & Hall: London, 1995; 40-42.
12. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343 871-881.
13. Verbeke G, Lesaffre E. A linear mixed-effects model with heterogeneity in the random-effects population. Journal of the American Statistical Association 1996; 91:217-221.
14. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989; 8:431-440.
15. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11:167-178.
16. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16:1515-1527.
17. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine 2001; 20:3175-3188.
18. Wang Y, Taylor JMG. A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 2002; 58 803-812.
19. Cowles MK. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Statistics in Medicine 2002; 21:811-834.
20. Voest EE, Van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with log (relative risk)) as main objectives. European Journal of Cancer Clinical Oncology 1989; 25 711-720.
21. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? a statistical overview. British Journal of Cancer 1988; 57:615-618.
22. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trails with failure time end points. Applied Statistics 2001; 50 405-422.
23. Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M. Validation of surrogate endpoints; in multiple clinical trials with discrete outcomes. Biometrical Journal 2002; 44:921-935.
24. Molenberghs G, Geys H, Buyse M. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Statistics in Medicine 2001; 20:3023-3038.
25. Gail MH, Pfeiffer R, Van Houwelingen HC, Carrot RJ. On meta-analytic assessment of surrogate outcomes. Biostatistics 2000; 1:231-246.
26. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Statistics in Medicine 1995; 14:2057-2079.